23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Conference Call February 7, 2024 4:30 PM ET

Company Participants

Ian Cooney - Senior Director of Investor Relations

Anne Wojcicki - Co-Founder and Chief Executive Officer

Joseph Selsavage - Interim Chief Financial and Accounting Officer

Jennifer Low - Head of Therapeutics Development

Bill Richards - Head of Therapeutics Discovery

Conference Call Participants

Steven Mah - TD Cowen

Operator

Hello, and welcome to 23andMe's Fiscal Year 2024 Third Quarter Financial Results Conference Call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session.

I would like to turn the call over to Ian Cooney, Senior Director of Investor Relations at 23andMe to lead off the call. Thank you. Please go ahead.

Ian Cooney

Thank you, Valerie. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the third quarter. A replay of today's webcast will also be available on our website. Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call.

Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures, important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release.

Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Joe Selsavage, our Interim Chief Financial and Accounting Officer; Jennifer Low, our Head of Therapeutics Development; and Bill Richards, Head of Therapeutics Discovery; will join us for Q&A.

I'd now like to turn the call over to Anne.

Anne Wojcicki

Thank you, Ian. The third quarter was busy and productive at 23andMe. We made meaningful strategic progress across our three businesses. We introduced our first integrated care offering with Total Health, signed a non-exclusive research agreement with GSK and filed our second IND in Therapeutics. I am extremely proud of the effort put forth by our team as we work towards creating a new future of healthcare powered by genetics.